Navigation Links
Boston Scientific Completes $1.05 Billion Senior Notes Offering
Date:8/13/2013

NATICK, Mass., Aug. 13, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the company's shelf registration statement.  The public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.  

The company previously announced that it intends to use the net proceeds from the offering, together with borrowings under its recent $400 million term loan facility, to redeem all or a portion of its (i) 5.450% notes due June 15, 2014, of which $600 million aggregate principal amount was outstanding as of the date hereof (the "June 2014 Notes"), and (ii) 4.500% notes due January 15, 2015, of which $850 million aggregate principal amount was outstanding as of the date hereof (the "January 2015 Notes"), and to pay related fees, expenses and premiums.   Following the completion of the offering, on August 13, 2013 the company provided the trustee with redemption notices to redeem all of the June 2014 Notes and the January 2015 Notes on September 12, 2013.  The company expects to record an after-tax one-time charge of approximately $45 million (or $0.03 per share) during the third quarter of 2013 associated with the redemption, which the company noted was not included in its previously announced GAAP earnings guidance.  This charge will not impact the company's adjusted earnings.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. 


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
2. American Laboratory Trading Continues Steady Growth with Expansion in Boston
3. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
4. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
5. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
6. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
7. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
8. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. Boston College researchers unique nanostructure produces novel plasmonic halos
11. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2005 discovery of an enzyme that is a natural ... Diego (UCSD) School of Medicine have now identified two ... for therapies to treat diabetes, heart and neurological disease. ... professor of pharmacology, and colleagues are published in the ...
... years, orthopedic surgeon Dennis Crawford, M.D., Ph.D., of Oregon ... tissue for transplant to treat some of his patients ... this unfortunate and ironic," explained Crawford, assistant professor of ... and a specialist in sports medicine. "Oregonians, it turns ...
... cancer care was $2.3 billion in the first year after diagnosis, ... the Journal of the National Cancer Institute . The time ... cancer care varied widely, they write. , Several studies have ... attempted to include a patient's time associated with cancer care, such ...
Cached Biology News:UCSD researchers discover variants of natural tumor suppressor 2OHSU surgeon implants donated tissue allografts 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3
... Mouse monoclonal [PRMT5-21] to PRMT5 Arginine ... which has only recently been linked to ... PRMT enzymes have been identified in mammalian ... have essential regulatory functions by methylation of ...
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
Biology Products: